NASDAQ: $MIRM A Breakthrough for Rare Disease Patients The landscape of treatment for Fibrodysplasia Ossificans Progressiva (FOP) has officially changed. The FDA has recently approved Atrebioz (zilurgisertib), providing a significant new therapeutic option for both adult and pediatric patients living with this incredibly rare and debilitating condition. Understanding FOP FOP is a progressive genetic disorder…